Shen Yuanming, Tang Sangsang, Zhou Yumei, Zhang Qiuxue, Chen Tingting, Li Jingnan, Wang Yu, Wan Xiaoyun, Lu Weiguo, Xu Junfen
Department of Gynecologic Oncology, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Wuhan Kingwise Biotechnology Company, Wuhan, Hubei, China.
J Low Genit Tract Dis. 2025 Jan 1;29(1):60-67. doi: 10.1097/LGT.0000000000000850. Epub 2024 Dec 2.
The aim of the study was to investigate the distribution and association between human papillomavirus (HPV) genotypes and integration as well as their correlation with cervical lesions.
Two hundred seven patients diagnosed with high-grade vaginal intraepithelial neoplasia (HG-VaIN) were recruited from the Women's Hospital School of Medicine Zhejiang University between 2015 and 2021 and assayed for HPV genotyping. HPV integration sequencing analysis was conducted using tissues from 53 patients with HG-VaIN and 4 patients with invasive vaginal carcinoma (IVC), along with paired cervical lesion specimens.
A total of 207 patients with HG-VaIN were categorized as having cervical lesions unrelated to HG-VaIN (group A, 71 patients, 34.30%) or cervical lesion-related HG-VaIN (group B, 136 patients, 65.70%). With an average follow-up of 42.19 months, 12 of 153 patients progressed to IVC and were all from group B. HPV16 infection and the presence of cervical lesions were the 2 main factors associated with disease progression, with cervical lesion coexistence being an independent factor. Compared with group A (5/20, 25%), group B (17/33, 51.52%) showed a higher rate of HPV integration, as demonstrated using HPV integration sequencing analysis, with HPV16 being the most integrated genotype (72.73%). The integration analysis of 4 patients with IVC paired with cervical lesion specimens showed that 3 of the 4 pairs exhibited the same HPV infection and integration sites, indicating a high degree of homology in HPV integration between cervical lesions and HG-VaIN-induced IVC.
Patients with HG-VaIN associated with cervical lesions exhibited a higher risk of malignant transformation, necessitating more proactive treatment approaches.
本研究旨在调查人乳头瘤病毒(HPV)基因型的分布及其与整合的关联,以及它们与宫颈病变的相关性。
2015年至2021年间,从浙江大学医学院附属妇产科医院招募了207例被诊断为高级别阴道上皮内瘤变(HG-VaIN)的患者,并对其进行HPV基因分型检测。对53例HG-VaIN患者和4例浸润性阴道癌(IVC)患者的组织以及配对的宫颈病变标本进行HPV整合测序分析。
207例HG-VaIN患者被分为与HG-VaIN无关的宫颈病变(A组,71例,34.30%)或与宫颈病变相关的HG-VaIN(B组,136例,65.70%)。平均随访42.19个月,153例患者中有12例进展为IVC,且均来自B组。HPV16感染和宫颈病变的存在是与疾病进展相关的两个主要因素,宫颈病变共存是独立因素。HPV整合测序分析显示,与A组(5/20,25%)相比,B组(17/33,51.52%)的HPV整合率更高,其中HPV16是整合率最高的基因型(72.73%)。对4例IVC患者与宫颈病变标本的整合分析显示,4对中有3对表现出相同的HPV感染和整合位点,表明宫颈病变与HG-VaIN诱导的IVC之间的HPV整合具有高度同源性。
与宫颈病变相关的HG-VaIN患者发生恶性转化的风险更高,需要采取更积极的治疗方法。